TickerSpark Feed

NVS coverage

Every article, report, and earnings note where NVS appears.

Gene Therapy Stocks That Turn Science Into Sales: 7 Picks

A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

Sep 22, 2026·13 MIN

gene therapy

Trending StockNVS

Novartis AG (NVS) falls 12.7% after Phase III setbacks

Novartis AG (NVS) falls sharply after two late-stage trial failures hit investor confidence. The selloff reflects lost pipeline value, especially for pelacarsen, even as the company’s core business remains profitable and growing.

Sep 8, 2026·6 MIN

Research ReportNVS

Novartis (NVS): Growth Drivers Offset Entresto Erosion

Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.

Sep 1, 2026·22 MIN

Healthcare Drug Manufacturers - General Pharmaceuticals

Trending StockNVS

Novartis AG (NVS) rises on remibrutinib MS data

Novartis AG (NVS) rises after reporting positive Phase III data for remibrutinib in relapsing multiple sclerosis. The late-stage results boosted investor confidence in the company’s pipeline, even as traders weighed regulatory risk, competition in MS, and a separate clinical setback in another program.

Sep 1, 2026·6 MIN

OpinionLLY

Eli Lilly is turning obesity demand into an access story now

Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.

Jun 28, 2026·4 MIN

Healthcare Obesity Drugs Medicare

OpinionMRK

Merck’s latest data may have bought it more time than bears want to admit

Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.